Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

To identify a recommended phase II dose for the second generation glycinamide ribonucleotide transformylase (GARFT) inhibitor, AG2034, administered by intravenous bolus every 3 weeks without folate supplementation and to describe AG2034 pharmacokinetics. Adults with advanced malignancies were enroll...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2000, Vol.45 (5), p.423-427
Hauptverfasser:	ROBERTS, J. D, SHIBATA, S, PARADISO, L. J, CLENDENINN, N. J, SPICER, D. V, MCLEOD, H. L, TOMBES, M. B, KYLE, B, CARROLL, M, SHEEDY, B, COLLIER, M. A, PITHAVALA, Y. K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy Drug Administration Schedule Enzyme Inhibitors - therapeutic use Female Glutamates - adverse effects Glutamates - pharmacokinetics Glutamates - therapeutic use Humans Hydroxymethyl and Formyl Transferases - antagonists & inhibitors Male Medical sciences Middle Aged Neoplasms - drug therapy Pharmacology. Drug treatments Phosphoribosylglycinamide Formyltransferase Pyrimidines - adverse effects Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!